Identification

Name
Hypoxanthine
Accession Number
DB04076  (EXPT01767)
Type
Small Molecule
Groups
Experimental
Description

A purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway. [PubChem]

Structure
Thumb
Synonyms
Not Available
Categories
UNII
2TN51YD919
CAS number
68-94-0
Weight
Average: 136.1115
Monoisotopic: 136.03851077
Chemical Formula
C5H4N4O
InChI Key
FDGQSTZJBFJUBT-UHFFFAOYSA-N
InChI
InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
IUPAC Name
7H-purin-6-ol
SMILES
OC1=NC=NC2=C1NC=N2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UPurine nucleoside phosphorylaseNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Thioguanine Action PathwayDrug action
AMP Degradation (Hypoxanthine Route)Metabolic
Purine MetabolismMetabolic
AICA-RibosiduriaDisease
Xanthine Dehydrogenase Deficiency (Xanthinuria)Disease
Azathioprine Action PathwayDrug action
Operon: De Novo Purine Nucleotide Biosynthesis InactivationSignaling
Adenosine Deaminase DeficiencyDisease
Molybdenum Cofactor DeficiencyDisease
Xanthinuria Type IDisease
Xanthinuria Type IIDisease
Operon: Cytosine Transport Inactivation IISignaling
Purine MetabolismMetabolic
Purine Nucleoside Phosphorylase DeficiencyDisease
Mercaptopurine Action PathwayDrug action
Adenine Phosphoribosyltransferase Deficiency (APRT)Disease
Operon: Glycine Cleavage System Inactivation IIISignaling
Adenylosuccinate Lyase DeficiencyDisease
Lesch-Nyhan Syndrome (LNS)Disease
Gout or Kelley-Seegmiller SyndromeDisease
Mitochondrial DNA Depletion SyndromeDisease
Myoadenylate Deaminase DeficiencyDisease
Adenine and Adenosine Salvage IMetabolic
Purine Ribonucleosides DegradationMetabolic
Purine Deoxyribonucleosides DegradationMetabolic
Adenosine Nucleotides Degradation Metabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Hypoxanthine.Approved, Investigational
AcenocoumarolThe serum concentration of Hypoxanthine can be increased when it is combined with Acenocoumarol.Approved, Investigational
AcetaminophenThe serum concentration of Hypoxanthine can be increased when it is combined with Acetaminophen.Approved
AdalimumabThe serum concentration of Hypoxanthine can be decreased when it is combined with Adalimumab.Approved
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Hypoxanthine.Approved, Investigational
AlprazolamThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Hypoxanthine.Approved, Illicit, Investigational
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Hypoxanthine.Approved, Illicit, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Hypoxanthine.Approved, Illicit
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Hypoxanthine.Approved, Investigational
BortezomibThe serum concentration of Hypoxanthine can be increased when it is combined with Bortezomib.Approved, Investigational
CaffeineThe metabolism of Hypoxanthine can be decreased when combined with Caffeine.Approved
CarbamazepineThe serum concentration of Hypoxanthine can be decreased when it is combined with Carbamazepine.Approved, Investigational
ChlorpromazineThe serum concentration of Hypoxanthine can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorzoxazoneThe serum concentration of Hypoxanthine can be increased when it is combined with Chlorzoxazone.Approved
CimetidineThe metabolism of Hypoxanthine can be decreased when combined with Cimetidine.Approved, Investigational
CiprofloxacinThe serum concentration of Hypoxanthine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
ClonazepamThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Hypoxanthine.Approved, Illicit
ClonidineThe serum concentration of Hypoxanthine can be increased when it is combined with Clonidine.Approved
ClorazepateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Hypoxanthine.Approved, Illicit
Cyproterone acetateThe serum concentration of Hypoxanthine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DiazepamThe therapeutic efficacy of Diazepam can be decreased when used in combination with Hypoxanthine.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe serum concentration of Hypoxanthine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylpropionThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Hypoxanthine.Approved, Illicit
DinoprostoneThe serum concentration of Hypoxanthine can be increased when it is combined with Dinoprostone.Approved
DoxepinThe serum concentration of Hypoxanthine can be increased when it is combined with Doxepin.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Hypoxanthine.Approved, Vet Approved
ErythromycinThe metabolism of Hypoxanthine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Hypoxanthine.Approved
EstradiolThe serum concentration of Hypoxanthine can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EthosuximideEthosuximide may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved
EtoposideThe serum concentration of Hypoxanthine can be increased when it is combined with Etoposide.Approved
EverolimusThe metabolism of Hypoxanthine can be decreased when combined with Everolimus.Approved
FlunarizineFlunarizine may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved
FluorouracilThe serum concentration of Hypoxanthine can be increased when it is combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Hypoxanthine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Hypoxanthine can be decreased when combined with Fluvoxamine.Approved, Investigational
FollitropinThe serum concentration of Hypoxanthine can be increased when it is combined with Follitropin.Approved
GabapentinGabapentin may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ImipramineThe serum concentration of Hypoxanthine can be increased when it is combined with Imipramine.Approved
Interferon Alfa-2b, RecombinantThe metabolism of Hypoxanthine can be decreased when combined with Interferon Alfa-2b, Recombinant.Approved
Interferon alfa-n3The metabolism of Hypoxanthine can be decreased when combined with Interferon alfa-n3.Approved, Investigational
Interferon beta-1aThe metabolism of Hypoxanthine can be decreased when combined with Interferon beta-1a.Approved, Investigational
Interferon beta-1bThe metabolism of Hypoxanthine can be decreased when combined with Interferon beta-1b.Approved
Interferon gamma-1bThe metabolism of Hypoxanthine can be decreased when combined with Interferon gamma-1b.Approved, Investigational
IsoprenalineThe serum concentration of Hypoxanthine can be decreased when it is combined with Isoprenaline.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Hypoxanthine.Approved
LamotrigineLamotrigine may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
LevetiracetamLevetiracetam may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
LidocaineThe serum concentration of Hypoxanthine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Hypoxanthine can be increased when it is combined with Liothyronine.Approved, Vet Approved
LorazepamThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Hypoxanthine.Approved
Magnesium sulfateMagnesium sulfate may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational, Vet Approved
MethimazoleThe serum concentration of Hypoxanthine can be increased when it is combined with Methimazole.Approved
MethsuximideMethsuximide may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Hypoxanthine.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Hypoxanthine.Approved
MoxifloxacinThe metabolism of Hypoxanthine can be decreased when combined with Moxifloxacin.Approved, Investigational
NaproxenThe serum concentration of Hypoxanthine can be increased when it is combined with Naproxen.Approved, Vet Approved
NortriptylineThe serum concentration of Hypoxanthine can be increased when it is combined with Nortriptyline.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Hypoxanthine.Approved
NystatinThe metabolism of Hypoxanthine can be decreased when combined with Nystatin.Approved, Vet Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Hypoxanthine.Approved, Investigational
Peginterferon alfa-2aThe metabolism of Hypoxanthine can be decreased when combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Hypoxanthine can be increased when it is combined with Peginterferon alfa-2b.Approved
PhenobarbitalThe serum concentration of Hypoxanthine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Hypoxanthine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Hypoxanthine.Approved
PhenytoinThe serum concentration of Hypoxanthine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Hypoxanthine.Approved, Investigational
PregabalinPregabalin may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Illicit, Investigational
PropafenoneThe serum concentration of Hypoxanthine can be increased when it is combined with Propafenone.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Hypoxanthine.Approved, Investigational
PropylthiouracilThe serum concentration of Hypoxanthine can be increased when it is combined with Propylthiouracil.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Hypoxanthine.Approved
RifampicinThe metabolism of Hypoxanthine can be increased when combined with Rifampicin.Approved
Salmon CalcitoninThe serum concentration of Hypoxanthine can be increased when it is combined with Salmon Calcitonin.Approved, Investigational
TerbinafineThe serum concentration of Hypoxanthine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Hypoxanthine.Approved
TheophyllineThe serum concentration of Hypoxanthine can be increased when it is combined with Theophylline.Approved
TiclopidineThe metabolism of Hypoxanthine can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Hypoxanthine.Approved
TopiramateTopiramate may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved
TrimethadioneTrimethadione may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Valproic AcidValproic Acid may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
VerapamilThe serum concentration of Hypoxanthine can be increased when it is combined with Verapamil.Approved
VigabatrinVigabatrin may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved
VinpocetineVinpocetine may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
WarfarinThe serum concentration of Hypoxanthine can be increased when it is combined with Warfarin.Approved
ZonisamideZonisamide may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Alvin J. Glasky, Heinrich Bollinger, Hans Rudolf Muller, "Methods of synthesis for 9-substituted hypoxanthine derivatives." U.S. Patent US06849735, issued February 01, 2005.

US06849735
General References
Not Available
External Links
Human Metabolome Database
HMDB0000157
KEGG Compound
C00262
PubChem Compound
790
PubChem Substance
46507200
ChemSpider
768
BindingDB
50200102
ChEBI
17368
ChEMBL
CHEMBL1427
HET
HPA
Wikipedia
Hypoxanthine
PDB Entries
1a9q / 1a9r / 1a9t / 1bdh / 1bdi / 1jfs / 1jft / 1jh9 / 1pnr / 1qp0
show 39 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)150 dec °CPhysProp
water solubility700 mg/L (at 23 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-1.11HANSCH,C ET AL. (1995)
logS-2.29ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility13.0 mg/mLALOGPS
logP-0.55ALOGPS
logP-0.048ChemAxon
logS-1ALOGPS
pKa (Strongest Acidic)8.72ChemAxon
pKa (Strongest Basic)2.66ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.69 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity35.5 m3·mol-1ChemAxon
Polarizability11.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.9758
Caco-2 permeable-0.7161
P-glycoprotein substrateNon-substrate0.6693
P-glycoprotein inhibitor INon-inhibitor0.9462
P-glycoprotein inhibitor IINon-inhibitor0.9626
Renal organic cation transporterNon-inhibitor0.8869
CYP450 2C9 substrateNon-substrate0.8095
CYP450 2D6 substrateNon-substrate0.7824
CYP450 3A4 substrateNon-substrate0.6692
CYP450 1A2 substrateInhibitor0.6493
CYP450 2C9 inhibitorNon-inhibitor0.913
CYP450 2D6 inhibitorNon-inhibitor0.9212
CYP450 2C19 inhibitorNon-inhibitor0.8549
CYP450 3A4 inhibitorNon-inhibitor0.9202
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8962
Ames testNon AMES toxic0.6541
CarcinogenicityNon-carcinogens0.9686
BiodegradationNot ready biodegradable0.8452
Rat acute toxicity2.1622 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9781
hERG inhibition (predictor II)Non-inhibitor0.9305
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS)GC-MSsplash10-0159-3970000000-0d844fae4a1ffe158823
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-014i-1790000000-ae93bf8bf07b30b65e1a
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS)GC-MSsplash10-00di-9340000000-1184c503fb61344c4853
GC-MS Spectrum - GC-MS (2 TMS)GC-MSsplash10-014i-3590000000-a419976950afe7934cbc
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-000i-9800000000-9c266d6963658e9d2cf1
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0159-3970000000-0d844fae4a1ffe158823
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-1790000000-ae93bf8bf07b30b65e1a
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00di-9340000000-1184c503fb61344c4853
GC-MS Spectrum - GC-MSGC-MSsplash10-014i-3590000000-a419976950afe7934cbc
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-2890000000-3be4d08be45781881bc1
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-1590000000-bb6f003bfa7bd04628a1
Mass Spectrum (Electron Ionization)MSsplash10-000i-8900000000-ebf57ea530a2d4e31ffa
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-000i-0900000000-2b36c20acd9973b317f5
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-0api-9800000000-fb4e3cccb7d27d119feb
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-0aor-9200000000-33c2f9eedf9a878530be
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-000i-9800000000-9c266d6963658e9d2cf1
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0910000000-4da64abddc3ac8ab573a
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-014i-1900000000-859f61101b12be0b2978
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-014i-1900000000-f5d899e7988568d5bcab
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0900000000-e19e6d04568d3560eb4a
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0910000000-8def0d2ec82152826763
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-014i-2900000000-a8361951a2f702a217c7
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0900000000-3f653a7c81b328e46cb5
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-014i-0080290000-be98ce43421dbf9007fa
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-000i-0930030000-56ea204dcb077bc174c2
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0006-9000000000-4c2d1980f9e5e4b720a5
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-000i-0900000000-26b3c93bc9dea5a88032
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-000i-1900000000-c367cd4c23aea0f74ecb
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-000l-8900000000-91e35cdcc11d357119f0
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-0006-9100000000-4fb8f4ee2d35aa874617
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-014l-9000000000-7934b3037f39d69fc40a
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-014i-9000000000-ad93e267446292bf247b
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-014i-9000000000-4b8f9e13ed7adf0888c2
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-014i-9000000000-f295755f591e27bb9f07
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-014i-9000000000-aee48a44f42a4b767844
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-014i-9000000000-f5ebd92e86cf00f28cf1
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-014i-9000000000-9a1ad1aa2d8fb621b608
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-e038598825c3f5207cc7
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01p9-0900000000-3bd84665737348c27328
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-07w9-9500000000-698bc04ff79f3f4ad849
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-43405c4438c54f7586dd
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-b6dc602a3e50b2f56044
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-066r-9500000000-3766c4c21fc8f20d22a6
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-1900000000-c367cd4c23aea0f74ecb
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000l-8900000000-f8c3fcf312f201115f52
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9100000000-1088187ef16c41e5fd58
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014l-9000000000-7934b3037f39d69fc40a
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-9000000000-ad93e267446292bf247b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-9000000000-fba535f8767b852493f1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0900000000-26b3c93bc9dea5a88032
MS/MS Spectrum - , negativeLC-MS/MSsplash10-000l-5900000000-835823cc21e116df8128
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-9000000000-4b8f9e13ed7adf0888c2
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-9000000000-f295755f591e27bb9f07
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-9000000000-aee48a44f42a4b767844
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-9000000000-f5ebd92e86cf00f28cf1
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-9000000000-9a1ad1aa2d8fb621b608
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000i-2900000000-dc5e86acd04180efda0a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-2900000000-a8361951a2f702a217c7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-3f653a7c81b328e46cb5
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0900000000-eff9983d19a7717c7d0d
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
Hypoxanthines
Alternative Parents
6-oxopurines / Pyrimidones / Vinylogous amides / Imidazoles / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides
show 1 more
Substituents
6-oxopurine / Hypoxanthine / Pyrimidone / Pyrimidine / Azole / Imidazole / Vinylogous amide / Heteroaromatic compound / Azacycle / Organic oxide
show 7 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
oxopurine, nucleobase analogue, purine nucleobase (CHEBI:17368) / Purine alkaloids (C00262) / a purine-related compound, a purine base (HYPOXANTHINE)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Purine-nucleoside phosphorylase activity
Specific Function
The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine ...
Gene Name
PNP
Uniprot ID
P00491
Uniprot Name
Purine nucleoside phosphorylase
Molecular Weight
32117.69 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Smith AG, Davies R, Dalton TP, Miller ML, Judah D, Riley J, Gant T, Nebert DW: Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics. 2003 Jan;111(1T):45-51. [PubMed:12735109]

Drug created on June 13, 2005 07:24 / Updated on August 11, 2018 16:54